Progress assessments based on current long-term and real-world data

A broad spectrum of systemic agents is now available for the treatment of moderate to severe psoriasis. At this year’s DDG congress “Dermatology compact + practical”, various studies were presented on the biologics ixekizumab, bimekizumab and risankizumab, as well as the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib, among others, which focused on the evaluation of long-term therapeutic effects and treatment outcomes in everyday life.